摘要
目的:观察重组人白细胞介素鄄11(recombinatehumaninterleukin11熏rhIL鄄11)治疗化疗后血小板减少的疗效和毒性,以及用药后血小板变化的规律和特点。方法:20例(47周期)化疗后血小板减少患者接受rhIL鄄1125μg·kg-1·d-1皮下注射,平均用药6d,同一患者各周期的化疗方案及剂量强度相同。结果:第1、2周期化疗前血小板基础值分别为穴165.0±65.2雪×109/L和穴346.4±78.3雪×109/L;应用rhIL鄄11的天数分别为(7.0±5.7)d和(4.5±6.7)d;化疗后血小板计数小于50×109/L的平均持续天数分别为(5.0±3.6)d和(3.5±3.9)d;差异均有统计学意义。外周血血小板计数回升天数平均为4d,有12个周期血小板计数最高值大于400×109/L,血小板计数最高值出现在应用rhIL鄄11后(17.0±5.5)d;主要不良反应包括水肿、乏力、头晕头痛、肌肉关节疼痛。结论:rhIL鄄11能有效治疗化疗所致的血小板减少,血小板计数回升相对缓慢,作用持续时间较长,耐受性好。
Objective: To observe the effectiveness and safety profile of recombinate human interleukin 11 (rhIL-11) in the treatment of chemotherapy-induced thrombocytopenia. Methods: Twenty patients (47 cycles) with chemotherapy-induced thrombocytopenia received rhIL-11 at the dose of 25 μg·kg-1·d-1 subcutaneously for 6 days. The chemotherapy regimen and treatment intensity remained unchanged in the same patient. Results: Baseline platelet counts before the 1st and 2nd cycles of chemotherapy were (165.0±65.2)×109/L and (346.4±78.3)×109/L, and rhIL-11 was given for (7.0±5.7) days and (4.5±6.7)days in the 1st and 2nd cycles, respectively. Median duration of a post-chemotherapy platelet count below 50×109/L were (5.0±3.6)days and (3.5±3.9)days for the 1st and 2nd cycles, respectively. The median time required for a platelet recovery was 4 days. Platelet count reached 400×109/L in 12 chemotherapy cycles. The maximum platelet count appeared at day 17 after rhIL-11 administration. Major adverse reaction included edema, headache, and muscle and joint pain. Conclusion: rhIL-11 is an effective and safe agent for the management of chemotherapy-induced thrombocytopenia, with a relatively slow but sustained recovery of platelet count.
出处
《山东大学学报（医学版）》
CAS
2004年第5期590-592,共3页
Journal of Shandong University:Health Sciences
